Omnicell, Inc. (OMCL)
Nasdaq · Healthcare · Health Information Services
$34.64+3.10%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.6B
- P/E (trailing)
- 41.2
- Forward P/E
- 16.6
- 52-week range
- $29.06 – $55.00
- 52-week change
- +10.09%
- EPS (trailing)
- $0.84
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $1.2B (+6.53%)
- Net income
- $2.1M
- Operating margin
- 0.4%
- Diluted EPS
- $0.04
- Free cash flow
- $86.9M
From the company’s annual report on SEC EDGAR.
About Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services.
Headquarters: Fort Worth, United States · 3,485 employees · omnicell.com